intellectual property

Intellectual property theft, gun violence, scientific failure, and more

Novel uses for existing and failed drugs may save companies time and money in bringing new therapeutics to market.

This year, the developers of CRISPR gene-editing technology argued over patent rights, a researcher fought to unmask anonymous PubPeer commenters, US regulators considered “three-parent” babies, and troubles continued for Theranos.

The Scientist goes to court for a CRISPR patent interference case at the US Patent and Trademark Office.

Documents suggest Feng Zhang started working on CRISPR before Jennifer Doudna’s group published; researchers call for CRISPR technology to be shared openly

This week’s CRISPR patent hearing took a deep dive into the science of moving the gene-editing technology from prokaryotes to eukaryotic systems.

Tuesday morning, the US Patent and Trademark Office will hear oral arguments from the two parties that claim to have been the first to use CRISPR-Cas9 gene editing technology in eukaryotic cells.

Roger Tsien dies; the CRISPR patent dispute you’ve never heard of; immunotherapy for Alzheimer’s; Tasmanian devils developing resistance to transmissible cancer

A former researcher at the Broad Institute has suggested the University of California, Berkeley, team deserves credit for inventing the gene-editing technique.

A petition recently filed with the Supreme Court triggers renewed debate about the role of patents in the diagnostics sector.

The US Patent and Trademark Office is set to launch its “patent interference” inquiry into the competing patents on the gene-editing technology.

Caribou Biosciences receives a patent related to the gene-editing technology.

With one US patent awarded and many other applications under consideration for the popular genome-editing technology, companies are adopting multiple strategies to navigate the complex intellectual property landscape.

Leonard Hayflick has been unafraid to speak his mind, whether it is to upend a well-entrenched dogma or to challenge the federal government. At 86, he’s nowhere near retirement.

It’s never too early to start thinking about intellectual property rights—even for biologists doing basic research.

A genetic testing firm accused of infringing upon Myriad Genetics’s gene patents fights back in an attempt to wipe other patents out.

The USPTO offers guidance to its patent examiners on how to interpret the Supreme Court’s rulings in the recent Myriad and Prometheus cases.

A working group including members of the Lacks family approves the first projects to use the HeLa genome.

The America Invents Act (AIA) was a step in the right direction for US competitiveness and open innovation.

A newly instated patent law discriminates against academics and small biotechs.